Archive
544 articles, sorted by publication time.
The first participant has received an injection, formally moving epigenetic reprogramming from animal models and the imagination of longevity science into human safety testing; its real challenge is not reversing age, but whether it can repair damaged vision without crossing the line.
Tsingke Biotech brought RNA drug discussions together through an industry salon. The announcement itself was understated, but it reflects how nucleic acid drug development is shifting from target imagination to the next stage of competition: delivery, quality, and clinical verifiability.
As cancer treatment increasingly relies on subtle molecular signals, testing tools are no longer just observers; this IDE authorization allows an MRD test to take on a more formal monitoring role in a clinical trial.
The deal does more than strengthen a late-stage oncology pipeline. It also shows that large drugmakers are turning their attention to an unmet treatment gap in myelofibrosis: how to secure a next step for patients when JAK inhibitors are not effective enough.
Aggressive pediatric brain tumors have long lacked effective options; a first-in-human trial directs T cells toward three tumor proteins at once, with preliminary results suggesting it may extend survival for some patients, though a long path of validation remains before it can become a standard treatment.
PQ203 has been described as a potentially leading AI-designed cancer drug to knock on the door of approval; its significance lies not only in whether an algorithm can “invent” a molecule, but in whether clinical practice and regulation can prove that this design truly translates into a treatment patients can tolerate and benefit from.
The market is beginning to turn its attention to Ascentage, not only because cancer drug themes tend to stir imagination, but also because its pipeline now stands at the threshold where clinical evidence, regulatory pathways, and commercialization capabilities intersect.
This pilot is not a shortcut for new drug review. It is an effort by U.S. regulators to put drug quality, capacity resilience, and place-of-origin policy at the same table, testing whether faster and more stable manufacturing oversight can take shape.
The focus of this study is not the emergence of yet another large model, but placing AI in a problem closer to real clinical practice: how to form treatment judgments step by step across disease, comorbidities, contraindications, and evidence.
The U.S. regulator is moving construction issues for drugmakers and biologics manufacturers from the back end of applications to earlier design and preparation stages; whether this can shorten time to market will still depend on whether early communication truly translates into verifiable manufacturing quality.
From multiomics and spatial biology to cell and gene therapy manufacturing workflows, the deal shows that major suppliers are consolidating research tools, diagnostics, and bioprocessing capabilities into more complete platforms.
The deal not only gives Ipsen a late-stage hematologic oncology asset, but also pushes MDM2 inhibitors toward a tougher question: after JAK inhibitors prove insufficient, can they truly improve patients’ spleen burden and symptoms?